CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
emtricitabine/tenofovir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02495779
NCT02495779N/ACompleted
CompareCT.gov

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

James Egan·interventional·Posted Jul 13, 2015·Updated Mar 27, 2019

In Brief

A clinical study evaluating emtricitabine/tenofovir and CBT-based counseling for Human Immunodeficiency Virus. Completed, enrolled 54 participants across 2 sites.

Detailed Summary

This study is designed to investigate the acceptability, perceived need and uptake of short-term episodic Pre-Exposure Prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM). The overall objective is to determine the feasibility of a clinic-based Epi-PrEP implementation pilot project for 50 MSM (25/each of the 2 study sites) who report occasional condomless sex and who anticipate a period of high-risk while away from home (e.g. vacation) during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesUnited States
CollaboratorsFenway Community Health, National Institute of Mental Health (NIMH)

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 13, 2015
Enrollment StartJul 1, 2015
Primary CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.0 years ago

Interventions

emtricitabine/tenofovirdrug

Short-term episodic use for 2-3 weeks.

CBT-based counselingbehavioral

Brief CBT-based counseling to promote adherence